Your browser is no longer supported. Please, upgrade your browser.
ALXN Alexion Pharmaceuticals, Inc. monthly Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E30.65 EPS (ttm)3.73 Insider Own0.20% Shs Outstand220.60M Perf Week0.62%
Market Cap25.17B Forward P/E9.53 EPS next Y12.01 Insider Trans-1.53% Shs Float218.43M Perf Month9.71%
Income846.10M PEG2.58 EPS next Q2.47 Inst Own93.70% Short Float2.22% Perf Quarter0.72%
Sales5.54B P/S4.55 EPS this Y4.50% Inst Trans-0.43% Short Ratio2.51 Perf Half Y36.21%
Book/sh47.56 P/B2.41 EPS next Y9.23% ROA5.00% Target Price141.32 Perf Year15.94%
Cash/sh12.97 P/C8.83 EPS next 5Y11.88% ROE7.70% 52W Range72.67 - 121.50 Perf YTD5.81%
Dividend- P/FCF10.64 EPS past 5Y26.80% ROI16.90% 52W High-5.82% Beta1.35
Dividend %- Quick Ratio4.30 Sales past 5Y17.40% Gross Margin91.60% 52W Low57.47% ATR4.22
Employees3082 Current Ratio4.80 Sales Q/Q20.10% Oper. Margin7.20% RSI (14)58.19 Volatility3.38% 4.13%
OptionableYes Debt/Eq0.23 EPS Q/Q-337.60% Profit Margin15.30% Rel Volume0.96 Prev Close112.02
ShortableYes LT Debt/Eq0.22 EarningsJul 30 BMO Payout0.00% Avg Volume1.93M Price114.43
Recom2.20 SMA202.83% SMA507.00% SMA2009.65% Volume1,847,165 Change2.15%
Sep-01-20Resumed Stifel Hold $120 → $117
Jul-31-20Downgrade William Blair Outperform → Mkt Perform
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Sep-25-20 08:30AM  
Sep-24-20 02:56PM  
Sep-22-20 09:56AM  
Sep-21-20 02:00AM  
Sep-16-20 06:27AM  
Sep-15-20 10:09AM  
Sep-14-20 11:32AM  
08:00AM  
07:00AM  
Sep-09-20 08:30AM  
Sep-04-20 05:50PM  
04:45PM  
Sep-03-20 06:30AM  
Sep-02-20 03:58PM  
12:56PM  
Sep-01-20 08:37AM  
Aug-31-20 02:53PM  
01:33PM  
Aug-29-20 11:31AM  
Aug-24-20 01:12PM  
Aug-17-20 10:07AM  
Aug-06-20 08:00AM  
Aug-05-20 10:05AM  
Jul-31-20 07:31AM  
05:51AM  
Jul-30-20 07:32PM  
12:00PM  
11:14AM  
10:55AM  
07:50AM  
06:30AM  
Jul-29-20 08:27AM  
Jul-27-20 06:07PM  
03:25PM  
Jul-24-20 01:13PM  
Jul-23-20 12:32PM  
Jul-19-20 11:54AM  
Jul-16-20 06:30AM  
Jul-15-20 12:31PM  
Jul-14-20 01:11PM  
Jul-13-20 11:25AM  
Jul-08-20 01:21PM  
Jul-07-20 06:48PM  
10:00AM  
Jul-06-20 09:06AM  
Jul-02-20 12:10PM  
09:12AM  
08:48AM  
08:45AM  
Jul-01-20 09:43AM  
Jun-30-20 02:34PM  
Jun-29-20 02:00AM  
Jun-26-20 10:37AM  
Jun-25-20 12:18PM  
10:50AM  
Jun-24-20 09:12AM  
Jun-23-20 10:24AM  
Jun-17-20 08:30AM  
06:30AM  
05:51AM  
Jun-13-20 04:22PM  
Jun-12-20 10:09AM  
08:45AM  
08:20AM  
Jun-11-20 10:36PM  
11:10AM  
Jun-10-20 05:51AM  
Jun-09-20 01:51PM  
Jun-08-20 02:48PM  
12:29PM  
Jun-05-20 11:32AM  
Jun-04-20 06:30AM  
Jun-02-20 10:53AM  
Jun-01-20 05:50PM  
May-29-20 07:38PM  
04:32PM  
09:38AM  
May-28-20 03:36PM  
02:16PM  
09:49AM  
09:27AM  
06:03AM  
May-27-20 01:05PM  
May-15-20 04:48PM  
May-14-20 01:47PM  
09:31AM  
May-12-20 05:07PM  
12:34PM  
08:55AM  
May-08-20 06:35PM  
04:24PM  
May-07-20 01:24PM  
11:50AM  
May-06-20 04:22PM  
01:31PM  
12:25PM  
11:26AM  
11:19AM  
08:48AM  
08:05AM  
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaboration with Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale114.696,853785,98128,218Jun 09 05:05 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy82.0181,3796,673,9357,841,556Mar 18 06:46 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy79.7650,9024,059,7927,766,918Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy76.51102,4217,836,5857,720,234Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy78.76265,29820,894,7537,626,298Mar 18 06:45 PM